Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

June 2021

Phase I/II Updated Safety and Efficacy Results of Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Relapsed/Refractory Immune Thrombocytopenia

May 2021

Proof-of-concept for clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study

April 2021

Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients With Chronic Relapsing Pemphigus: BELIEVE Phase 2 Study (Part A)

March 2021

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

December 2020

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients With Heavily Pretreated Immune Thrombocytopenia

October 2020

Mechanisms of Topical Bruton Tyrosine Kinase Inhibitor PRN473 in Immune‑Mediated Models of Skin Disease

October 2020

Metabolism-Mediated Drug Interactions Between Ritonavir and Oral BTK Inhibitor Rilzabrutinib in Rats

October 2020

A Thorough QT Study to Evaluate the Effects of Oral Rilzabrutinib Administered Alone and With Ritonavir to Achieve Supratherapeutic Concentrations in Healthy Subjects

Advancing Promising Therapies